Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,803 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer.
Shah MA, Wainberg ZA, Catenacci DV, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2013;8(3):e54014. doi: 10.1371/journal.pone.0054014. Epub 2013 Mar 14. PLoS One. 2013. PMID: 23516391 Free PMC article. Clinical Trial.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2021 Dec 23;16(12):e0261994. doi: 10.1371/journal.pone.0261994. eCollection 2021. PLoS One. 2021. PMID: 34941969 Free PMC article.
Correction: Phase II Study Evaluating 2 Dosing Schedules of Oral Foretinib (GSK1363089), cMET/VEGFR2 Inhibitor, in Patients with Metastatic Gastric Cancer.
Shah MA, Wainberg ZA, Catenacci DVT, Hochster HS, Ford J, Kunz P, Lee FC, Kallender H, Cecchi F, Rabe DC, Keer H, Martin AM, Liu Y, Gagnon R, Bonate P, Liu L, Gilmer T, Bottaro DP. Shah MA, et al. Among authors: ford j. PLoS One. 2022 Oct 10;17(10):e0276211. doi: 10.1371/journal.pone.0276211. eCollection 2022. PLoS One. 2022. PMID: 36215283 Free PMC article.
Breast Cancer MRI Screening of Patients After Multiplex Gene Panel Testing.
Naghi LA, Culver JO, Ricker C, Sturgeon D, Kingham K, Hodan R, Chun NM, Kidd J, Bonner J, Hong C, Morales-Pichardo J, Mills M, Lindsey S, McDonnell K, Ladabaum U, Ford JM, Gruber SB, Kurian AW, Idos GE. Naghi LA, et al. Among authors: ford jm. JAMA Netw Open. 2025 Jan 2;8(1):e2454447. doi: 10.1001/jamanetworkopen.2024.54447. JAMA Netw Open. 2025. PMID: 39804645 Free PMC article.
VISTA-induced tumor suppression by a four amino acid intracellular motif.
Zhao Y, Andoh T, Charles F, Reddy P, Paul K, Goar H, Durdana I, Golder C, Hardy A, Juntilla MM, Yang SR, Lin CY, Sagiv-Barfi I, Geller BS, Moore S, Thakkar D, Boyd-Kirkup JD, Peng Y, Ford JM, Telli ML, Zhang S, Kurian AW, West RB, Yue T, Lipchik AM, Snyder MP, Gruber JJ. Zhao Y, et al. Among authors: ford jm. bioRxiv [Preprint]. 2025 Jan 5:2025.01.05.631401. doi: 10.1101/2025.01.05.631401. bioRxiv. 2025. PMID: 39803490 Free PMC article. Preprint.
Education Research: Utilization of Simulation in Residency Programs: A Survey of Adult Neurology Residency Program Directors.
Ghoshal S, Albin CSW, Malhotra NA, Asonye I, Budrow J, Stainman R, Kurzweil A, Bell M, Ford J, Kleyman I, Massad N, Mikhaeil-Demo Y, Wasserstrom B, Tchopev Z, Morris NA. Ghoshal S, et al. Among authors: ford j. Neurol Educ. 2024 Nov 14;3(4):e200156. doi: 10.1212/NE9.0000000000200156. eCollection 2024 Dec. Neurol Educ. 2024. PMID: 39748891 Free PMC article.
3,803 results